Minorities in clinical trials
This article was originally published in The Tan Sheet
Evening meeting to examine role of FDA, institutional review boards, other stakeholders "in the protection of human subjects in clinical trials as it relates to minority participation" slated for Aug. 22. Meeting will take place from 7:30 p.m.-9:30 p.m. at Meharry Medical School in Nashville, Tenn. For more information, contact FDA's Sandra Baxter at 615-781-5385...
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.